Key result
Robotic surgery adoption is challenged by high acquisition, maintenance, and training costs, alongside a lack of manufacturer transparency and insufficient cost-utility evidence.
Why the study?
Does the high cost of robotic surgery impede its accessibility and worldwide establishment?
Does the high cost of robotic surgery impede its accessibility and worldwide establishment?
The exorbitant and often non-transparent costs of robotic surgery systems present a significant challenge to their widespread accessibility and adoption.
Answers are grounded in this paper and cite their sources.
High robotic surgery costs may limit accessibility; leaves open whether benefits justify expenses pending stronger evidence.
With increasing market size and rising demand, the question arises whether the high cost impedes accessibility to robotic surgery. Despite all the apparent advantages robotic surgery offers to surgeons and patients, it is imperative for healthcare providers to weigh the insufficiently documented evidence for robotics against the exorbitant price. Aside from the high acquisition cost of robotic systems, the cost of instruments and accessories, maintenance, as well as the need for training, and the impact on procedural dynamics in the operating room factor into any cost–utility analysis. However, current perspectives provide an insufficient overview of available systems and their cost. And the lack of transparency and incomplete information provided by manufacturers impose a significant challenge to informed decision-making. This article gives a short overview of the cost of robotic surgery, what additional costs to consider, where to obtain information, and attempts to elaborate on the question of whether cost impedes the worldwide establishment of robotic surgery.
No takes yet. Share an insight, caveat, or question.
Eckhoff et al. (2023) conducted a review in Robotic surgery. Robotic surgery was evaluated. Robotic surgery adoption is challenged by high acquisition, maintenance, and training costs, alongside a lack of manufacturer transparency and insufficient cost-utility evidence.
Synapse has enriched 10 related papers. Consider them for comparative context: